Use of long-acting human recombinant soluble tumor necrosis factor a receptor in the preparation of drugs for preventing and treating severe liver injury on chronic liver disease

The use of long-acting soluble tumor necrosis factor α receptor (LHusTNFR) in the preparation of drugs to prevent and/or treat severe liver injury on chronic liver disease or hepatic necrosis on the basis of chronic liver diseases.

• The mentioned chronic liver disease with severe liver injury (also called severe liver injury on chronic liver disease) refers to diseases that occur in the presence of chronic liver disease and are caused by viruses, immune injury, toxins (or drugs), alcohol, or a high-fat diet;
• severe liver injury also refers to a class of liver diseases that result from the rapid deterioration of liver functions caused by a recently suffered major injury in the liver that induces acute and massive hepatocyte necrosis that can develop into multiple organ failure with a short-term mortality rate greater than 20%.
• The mentioned hepatocyte necrosis refers to acute and large area hepatocyte necrosis (massive/submassive hepatic necrosis), which is one of the characteristic manifestations of liver pathology.

A method for the prevention of severe liver injury on chronic liver disease and hepatocyte necrosis caused by chronic liver diseases wherein patients who require treatment are given LHusTNFR.

A method for the treatment of early-stage severe liver injury on chronic liver disease and early-stage hepatocyte necrosis caused by chronic liver diseases wherein patients who require treatment are given LHusTNFR.